Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2022-11-24 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东股份减持计划数量过半的进展公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the progress of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the number of shares reduced, the reduction method, and compliance with relevant regulations. It does not contain financial statements or detailed financial performance data. The content fits the description of a Major Shareholding Notification, which involves reporting changes in significant share ownership levels.
2022-11-24 Chinese
关于公司副总经理辞职的公告
Board/Management Information Classification · 100% confidence The document is a short announcement regarding the resignation of the company's vice general manager. It contains no financial data, no report references, and no regulatory filings beyond the management change. The content clearly relates to a change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is very short and focused solely on management change, confirming this classification.
2022-11-01 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board regarding the review and approval of the company's 2022 third quarter report. It states that the Supervisory Board has reviewed the third quarter report and found it compliant and accurate. However, the actual third quarter report is not included here; instead, it references that the full report is published separately on the CNINFO website with announcement number 2022-048. The document length is short (754 characters) and serves as a formal announcement of the Supervisory Board's approval of the quarterly report, not the report itself. According to the MENU VS MEAL RULE, this is an announcement related to a report, not the report itself. Therefore, the correct classification is Regulatory Filings (RNS), as it is a regulatory announcement about the supervisory board's resolution and the report's approval, not the full interim/quarterly report containing substantive financial data.
2022-10-28 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from the company regarding the approval of the 2022 third quarter report. It references the actual third quarter report published separately on a regulatory website (cninfo.com.cn) with a different announcement number. The document itself does not contain the financial data or the report but only the board's resolution and voting results. The document length is short (637 characters) and serves as an announcement of the board meeting decision rather than the report itself. Therefore, it fits best under Board/Management Information (MANG).
2022-10-28 Chinese
2022年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2022 Third Quarter Report" of 赛隆药业集团股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data including balance sheets, income statements, cash flow statements, and shareholder information for the third quarter of 2022. The document explicitly states it is unaudited and covers a period shorter than a full fiscal year, consistent with an interim or quarterly report. The length of the document (12,260 characters) and the presence of substantive financial data confirm it is the actual report, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-10-28 Chinese
关于公司控股股东部分股份质押延期的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the extension of a pledge on shares held by the controlling shareholder of the company. It details the number of shares pledged, the pledge period, and reassures investors about the absence of risks related to the pledge. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledge status, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Major Shareholding Notification (MRQ) or Transaction in Own Shares (POS) since it concerns pledge extension rather than share ownership changes or buybacks.
2022-10-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.